More shots on goal: Boehringer’s long-view playbook from IPF to obesity

Interconnections among kidney, liver and cardiometabolic diseases — including obesity — are creating opportunities to differentiate weight-loss drugs “beyond pounds on the scale,” and Boehringer Ingelheim is positioning itself to compete in that next phase, Brian Hilberdink, president, U.S. human pharma, told BioCentury.

Hilberdink said the company has leaned into partnering rather than big-ticket M&A, using frequent deals to build breadth across cardio-renal-metabolic disease — alongside other priority areas — and keep more shots on goal in the clinic...